Physician profile
Benjamin S Smith
NPI 1366445108
$6,953.13
in general payments reported to CMS, 2019-2025
40 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $534 · 2021: $1,168 · 2022: $1,172 · 2023: $1,444 · 2024: $883 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,688.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,018.07 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $751.95 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $603.33 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $572.07 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.35 | 2019-2025 | Jardiance, Cyltezo |
| Bayer Healthcare Pharmaceuticals INC. | $344.81 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $309.83 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Sunovion Pharmaceuticals INC. | $290.49 | 2020-2022 | |
| Lilly USA, LLC | $266.91 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $240.38 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $228.40 | 2021 | |
| Sumitomo Pharma America, INC. | $200.91 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $172.75 | 2020-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $161.03 | 2022 | |
| Glaxosmithkline, LLC. | $110.99 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.